Aims: Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control. This Phase 1 clinical trial assessed the safety and tolerability, pharmacokinetics and preliminary efficacy of a novel MetAP2 inhibitor, ZGN-1061. 
(VTE) events in the beloranib-treated groups compared to placebo in beloranib clinical trials. 8 Subsequent pre-clinical evaluation indicates that the prothrombotic effect of beloranib appears to be explained, at least in part, by extended endothelial cell (EC) exposure 10 that initiates an intracellular procoagulant signaling cascade. 11 The novel MetAP2 inhibitor, ZGN-1061, was selected for clinical development because of an improved pre-clinical safety profile, which included assessment of thrombosis potential, and in vitro and in vivo efficacy similar to that of beloranib. 10 This Phase 1 clinical trial assessed the safety (including coagulation-related biomarkers), tolerability, pharmacokinetics (PK) and preliminary efficacy of ZGN-1061 in healthy normal-weight individuals and in overweight and obese individuals.
2 | METHODS
| Clinical trial design
This was a first-in-human, Phase I, randomized, double-blind, placebo- 
| Single ascending dose (SAD) phase
Subjects were randomized to receive ZGN-1061 (0.2, 0.6, 1.2, 2.4, 3.6 or 4.8 mg) or placebo as a single subcutaneous (SC) 0.5 mL injection. The randomization ratio was 3:1 for ZGN-1061 dose relative to placebo for each dosing cohort. Dose escalation was based on the available safety, tolerability and PK results of ≥5 dosed subjects in the preceding group.
Subjects fasted overnight prior to pre-dose procedures until 4 hours after dosing. Subjects were confined to the trial site the afternoon prior to dosing (day 0) and remained in the clinic until day 3 assessments were completed. Subjects returned for an ambulatory visit on day 10.
| Multiple ascending dose (MAD) phase
Subjects were randomized to receive ZGN-1061 (0.2, 0.6 or 1.8 mg) or placebo twice weekly (BIW) as 0.5 mL SC injections for 4 weeks (8 total injections). The randomization ratio was 3:1 for ZGN-1061 dose relative to placebo for each dosing cohort. Dose escalation was based on safety, tolerability, PD and PK results in the preceding group. Subjects fasted overnight prior to pre-dose procedures at baseline, day 14 and day 28, and fasting continued until ≥4 hours after dosing. Subjects were confined to the trial site the morning prior to dosing (day 0) and remained until day 17 assessments were completed. Subjects returned to the trial site on days 20 and 23 and were released the following day after dosing. Subjects also returned to the trial site for ambulatory visits on days 25 and 28 (with optional overnight stay on days 27 to 29).
| Randomization and blinding
Randomization was conducted via a computer-generated randomization code produced by the Biostatistics department of PRA Health Sciences (The Netherlands). Double-blinding was maintained for the duration of the clinical trial; all subjects, the investigator and site personnel other than pharmacy personnel were blinded. Pharmacy personnel not involved in the conduct of the trial dispensed trial medication (placebo or ZGN-1061) in containers that differed only by subject
number. An unblinded Sponsor team monitored real-time safety. 
| Subjects

| Assessments
General safety and tolerability assessments included adverse events 
| Bioanalysis
The quantitative determination of ZGN-1061 in acidified EDTA plasma samples (lower limit of quantification [LLOQ] = 0.010 ng/mL) utilized solid-phase extraction, followed by ultra-high-performance liquid chromatography with tandem mass spectroscopy (File S1
Bioanalysis Methods).
| Analysis
Subject demographics, subject disposition, safety parameters and PK parameters were summarized descriptively by treatment group and separately for the SAD and MAD phases. Plasma PK parameters were estimated using non-compartmental analysis as appropriate. To assess the dose proportionality, a power model was applied as appropriate to the PK parameters, including maximum observed plasma concentration (C max ) and area under the plasma concentration-time curve up to time t, where t is the last point with concentrations above the LLOQ (AUC 0-t ). Statistical analysis of PD parameters was performed separately for the SAD and MAD phases using observed values by visit and treatment group and using an analysis of covariance model for the change from baseline value, with the baseline measure as a covariate and treatment as a fixed effect. All statistical analyses were performed using SAS version 9.3. Analysis of safety was conducted on the safety population, that is, all subjects who received at least 1 dose of the clinical trial drug. The PK population included all subjects who received at least 1 dose of ZGN-1061 and provided adequate blood samples for bioanalysis. The PD population included all subjects who received at least 1 dose of the clinical trial drug and were without major protocol violations.
3 | RESULTS
| Baseline demographics and subject characteristics
All 39 randomized subjects (28 to ZGN-1061 and 11 to placebo) completed the assessment period in the SAD phase. Subjects in the SAD phase were 69% white and 90% male, with a baseline (mean AEstandard and generally approached the LLOQ within 4 hours of dosing ( Figure S1 and Table S2 , Supporting Information). The mean C max and mean AUC 0-t of ZGN-1061 increased linearly with dose. Mean C max ranged from 0.5 to 18.7 ng/mL and mean AUC 0-t ranged from 0.2 to 21.6 h × ng/mL.
| MAD phase
After repeat dosing, ZGN-1061 was rapidly absorbed and cleared at all doses tested ( Figure 1 and Table S3 
There were no clinically meaningful or dose-dependent changes in clinical chemistry, haematology or urinalysis, ECG, vital signs, physical examination results or local tolerability measurements from baseline.
All AEs were mild, with the exception of 1 moderate AE of toothache in a subject in the 0.6 mg ZGN-1061 group. The most common AEs with ZGN-1061 were mild gastrointestinal issues (similar incidence for ZGN-1061 and placebo), headache, catheter site pain and proceduralrelated irritation (irritation related to a bracelet worn for subject identification) ( 3.5 | Pharmacodynamics
| Body weight and cardiometabolic measures
Mean baseline body weight in the MAD phase was lower in the placebo group than in the ZGN-1061 treatment groups in the PD population (Table 2) . A greater reduction in body weight from baseline to day 28 was observed with all doses of ZGN-1061 than with placebo ( Figure 3A) . The reduction in mean body weight with ZGN-1061 consisted of a gradual decline for the duration of the trial that rebounded after clinical trial drug administration was discontinued ( Figure 3B ).
ZGN-1061 treatment produced an apparent dose-response reduction in total amount of food consumed during the 30-minute meal challenge, with the highest dose of ZAF-1061 associated with an approximate 40% reduction in food consumption on day 28 compared to baseline (Table 2 ). There were also observed trends in reductions in waist circumference, low-density lipoprotein (LDL) cholesterol and hsCRP relative to placebo (Table 2 ). In a subset of subjects with abnormally elevated LDL cholesterol at baseline (≥130 mg/dL, N = 13), there was a trend toward a greater reduction in LDL cholesterol in the combined group of ZGN-1061-treated subjects (baseline mean AESD, Adverse events in the SAD and MAD phases were mild, for the most part, and did not result in clinical trial discontinuation. In the SAD phase, dose escalation was discontinued because exposure substantially exceeded the therapeutic range. There were no notable AEs or safety findings after single dosing of up to 4.8 mg. Repeat dosing during the MAD phase was also generally well tolerated, with mild headache and procedural-related irritation events (non-injection siterelated) reported more frequently than events with placebo.
All subjects were screened for signs of VTE prior to the clinical trial and were regularly monitored for evidence of VTE by D-dimer measurements taken at screening, pre-dose, during drug administration and at follow-up. D-dimer is a fibrin degradation product that is a conventional 
